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Use of prostate-specific antigen testing in Medicare beneficiaries: 
 Association with previous evaluation
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Abstract
Objective: Determine uptake of prostate-specific antigen (PSA) testing in Medicare benefi-
ciaries according to previous receipt of PSA testing.
Methods: A 5% random sample of men aged 67 years or older without a previous diagnosis of 
prostate cancer was identified through 2009–2012 Medicare claims. We measured the annualized 
frequency of PSA screening among men due for PSA testing, stratified by PSA testing use in the 
previous 2 years, and clustered by ordering provider.
Results: Throughout the study period, PSA testing use was consistently higher for men with 
previous screening than for men without previous screening. For men without previous screening, 
there was a decline in testing that was most pronounced in 2012. Compared with 2009, the cor-
responding odds ratios were 0.98 [95% confidence interval (CI) (0.96–1.00)] in 2010, 0.94 [95% 
CI (0.92–0.95)] in 2011, and 0.66 [95% CI (0.65–0.68)] in 2012. In contrast, for men with previous 
screening, PSA testing frequency was stable from 2009 to 2011, and declined to a lesser extent in 
2012 [odds ratio 0.80, 95% CI (0.79–0.81)].
Conclusion: Receipt of PSA testing is highly dependent on whether an individual was tested 
in the recent past. In previously unscreened men, the largest decrease occurred in 2012, which may 
reflect in part the publication of US Preventive Services Task Force guidelines, but there was much 
less impact among men already being screened.
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Introduction
Prostate cancer is among the most frequently 
diagnosed cancers in the United States, both 
overall and in the Medicare-eligible popula-
tion (aged 65 years or older) [1]. Despite the 
high incidence and mortality associated with 
prostate cancer [1], the merits of prostate-spe-
cific antigen (PSA) screening in the general 
population are controversial. In 2008, the US 
Preventive Services Task Force (USPSTF) ini-
tially determined that there was insufficient 
evidence to recommend or not recommend 
routine prostate cancer screening with either 
PSA testing or digital rectal examination 
in men younger than 75 years [2]. In con-
trast, it concluded that the potential harms 
of screening would outweigh the benefits in 
men aged 75 years or older. In May 2012, the 
revised USPSTF guidelines recommended 
that prostate cancer screening no longer be 
performed by either method in men who 
are of average risk of having prostate cancer 
[3]. Other guidelines, including those of the 
American Cancer Society [4], the American 
PSA testing in Medicare
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Urological Association [5], and most recently, the National 
Comprehensive Cancer Network [6] recommended that men 
who are aged 50–74 years, 55–69 years, and 45–75 years 
respectively and have at least a 10-year life expectancy should 
have an opportunity to make an informed decision with their 
health care provider about whether to be screened for pros-
tate cancer. In addition, the American Urological Association 
guidelines recommend every other year testing among men 
who elect to have PSA screening [5].
Previous studies have used administrative data, including 
Medicare claims and Veterans Administration files, to exam-
ine the use of PSA testing according to age and publication of 
practice guidelines and clinical trial data [7–12]. Studies have 
documented variability in the use of screening according to 
geographic region [12] and physician characteristics [11], as 
well as a modest decline in screening following the publica-
tion of the 2008 [8, 11, 13] and 2012 [14–17] USPSTF guide-
lines [2,3] and screening trial publications [18, 19]. Three 
recently published studies used data from the National Health 
Interview Survey [20–22] and reported declines in PSA test-
ing use following publication of the USPSTF guidelines. 
However, despite the consensus that if PSA testing is offered, 
it should be performed on a regular (i.e., annual or biannual) 
basis, all studies have used a cross-sectional approach to meas-
ure screening. In these studies, PSA testing was considered as 
a one-time event and patients were not stratified according to 
previous use of screening or whether they were up to date with 
screening.
We therefore performed a population-based analysis with 
Medicare claims data to determine the use of PSA testing 
according to receipt of previous screening. In addition to meas-
ures of previous PSA testing, our analyses also considered fac-
tors such as sociodemographics, comorbidity, and physician 
supply. We hypothesized that the frequency of screening did 
not change among men who were already undergoing testing 
but declined in men who were previously not screened.
Methods
Data sources
The study cohort included claims from a 5% random sample 
of Medicare beneficiaries from 2004 to 2012. On the basis of 
the selection criteria for the 5% sample, the same beneficiaries 
were contained in the sample from year to year. To measure 
the use of PSA testing, we included files from 2009 to 2012, 
with the 2004–2008 data used to exclude previous prostate 
cancer diagnoses and determine previous use of PSA  testing. 
The relevant files included the Medicare Carrier Files, the 
Medicare Outpatient Files, and the Medicare Beneficiary 
Summary Files.
In addition, we used the 2010 US Census data, which pro-
vided ZIP-code level information of socioeconomic status. 
These data were used as ecological measures in the patient-
level regression analyses. The 2010 American Medical 
Association Masterfile, which contains information on both 
American Medical Association members and nonmembers, 
was used to categorize physician density per 100,000 popula-
tion at the county level.
The sample was limited to men aged 67 years or older 
who were contained in the 5% random sample of Medicare 
beneficiaries and continuously enrolled. Because Medicare 
enrollment typically begins at age 65 years, this age restric-
tion was used so as to have at least a 2-year look-back period 
to exclude men with a previous diagnosis of prostate cancer 
or prostate carcinoma in situ [International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
185, 233.4, 602.3, V10.46], which have different guidelines, as 
well as to measure PSA testing use in the preceding 2 years. 
Also, because of the high likelihood of incomplete claims, 
we excluded beneficiaries who were enrolled in Medicare-
managed care plans during the look-back period as well as 
those who were not enrolled in Medicare Part A and Part B.
To limit the analysis to PSA testing performed for probable 
screening indications as opposed to surveillance or symptom 
evaluation, we used a previously developed and validated algo-
rithm to increase the specificity of PSA testing [6]. In addition 
to a prostate cancer diagnosis, this algorithm also excluded 
men with a history of prostatectomy, androgen deprivation 
therapy, or elevated PSA level, and also urinary symptoms 
within 3 months before the PSA test claim.
Measures
Demographic characteristics were obtained from Medicare 
claims, and included age and race. Ecological measures of 
socioeconomic status included median household income 
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and proportion of high school graduates among adults aged 
25 years or older. A previously validated, weighted comorbid-
ity index that included both outpatient and inpatient diagnosis 
codes was included for the 12-month to 1-month period before 
the PSA test date or the end of the follow-up period [23]. As 
previously defined, to exclude “rule out” diagnoses, a comor-
bid condition had to appear more than once in outpatient files. 
The Beneficiary Summary File contained fields for state buy-
in and dual eligibility, which indicate lower socioeconomic 
status and/or with heightened vulnerability. The geographic 
region of residence was divided into Northeast, Midwest, 
South, and West.
During each calendar month, we considered the propor-
tion of eligible men who received one or more PSA tests, 
divided by the number of men who were otherwise eligible 
for screening and who had not received a PSA test during 
the previous 24 months. Men were included in the numera-
tor only if they actually received a PSA test during that 
month, and the denominator changed from month to month 
as new men became due for testing. PSA tests were identi-
fied through relevant procedure codes (CPT-4 84153, G0103). 
To account for delays in obtaining screening, a 90-day exten-
sion from the beneficiary’s due date for repeated screening 
was used to satisfy the criterion for screening. This approach 
was previously used in a study of the impact of health care 
reform on receipt of mammography and colonoscopy [24]. 
Beneficiaries were censored at the month of death or disen-
rollment from fee-for-service Medicare plans on the basis of 
the Beneficiary Summary File. We also censored individuals 
at the time of prostate cancer diagnosis (ICD-9-CM 185) dur-
ing 2009–2012.
Analysis
We first summarized PSA testing frequency by calendar 
month according to whether the patient was due for screen-
ing during that month (i.e., no PSA test in the previous 24 
months). Because of the 90-day window to account for being 
up to date with testing, a cutoff for the due date of September 
30, 2012, was used, and patients with due dates after that were 
excluded for calculation of frequencies for October through 
December 2012. The analyses were stratified according to 
whether the patient had no evidence of PSA testing during the 
previous 2-year period, or whether the patient had undergone 
testing during the previous 2 years and was due for repeated 
screening.
Univariate analysis was used to determine the association 
of calendar year with the use of PSA testing. Because indi-
vidual patients were eligible for screening in more than 1 year, 
generalized estimating equation (GEE) logistic regression was 
used to account for within-patient correlation. In addition, as 
individual providers tend to have unique practice patterns with 
regard to PSA testing, we included physician clustering in the 
GEE regression models. We then used multivariate GEE mod-
els to determine the independent association of demographic, 
socioeconomic and clinical measures with receipt of PSA test-
ing. As in the monthly frequencies, the analyses were stratified 
according to the presence of previous PSA testing. For men 
with previous PSA testing, we also added a covariate for the 
time since the most recent PSA test.
The Medicare claims data were obtained through a data 
use agreement with the Centers for Medicare and Medicaid 
Services, and approval was obtained from the University 
Hospitals Cleveland Medical Center Institutional Review 
Board.
Results
Using the 5% random sample of Medicare beneficiaries 
in 2009–2012, we identified 1,614,857 eligible beneficiar-
ies. From this cohort, we excluded 1,201,421 for the follow-
ing non-mutually exclusive indications: age younger than 70 
years (n=696,971), enrollment in Medicare-managed care 
plans (n=442,615), lack of enrollment in Medicare Part B 
(n=435,579), prior prostate cancer diagnosis (n=5871), and 
enrollment because of end-stage renal disease or disability 
(n=23,188). The final sample consisted of 598,184 men, includ-
ing 333,514 (55.8%) with at least one PSA test and 264,670 
(44.2%) with no evidence of PSA testing.
The characteristics of men with and without PSA test-
ing are shown in Table 1. The age distribution of the group 
with PSA testing was somewhat in favor of older age com-
pared with the group without PSA testing, whereas the 
racial and ethnic distribution was similar between the two 
groups. The PSA group had a higher proportion of men with 
at least one comorbid condition. Men with PSA testing were 
PSA testing in Medicare
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Table 1. Demographic characteristics of men according to prostate-specific antigen testing
Without PSA testing With PSA testing P
Total 264,670 333,514
Mean age at cohort entry±SD (years) 76.1±7.9 76.1±6.5
Age at cohort entry (years) <0.0001
 67–69 117,475 (44.4%) 121,287 (36.4%)
 70–74 48,484 (18.3%) 79,596 (23.8%)
 75–79 37,737 (14.3%) 60,101 (18.0%)
 80+ 60,974 (23.0%) 72,530 (21.8%)
Ethnicity <0.0001
 White 225,940 (85.3%) 287,233 (86.1%)
 African American 22,184 (8.4%) 24,869 (7.5%)
 Other/unknown 16,546 (6.3%) 21,412 (6.4%)
 Hispanic 4975 (1.9%) 6437 (1.9%)
Comorbidity score <0.0001
 0 142,188 (53.7%) 126,235 (37.9%)
 1 45,405 (17.2%) 80,543 (24.1%)
 2 25,328 (9.5%) 43,309 (13.0%)
 3+ 51,749 (19.6%) 83,427 (25.0%)
Geographic region <0.0001
 Northeast 29,117 (11.0%) 32,785 (9.8%)
 Midwest 80,564 (30.4%) 73,265 (22.0%)
 South 93,648 (35.4%) 160,981 (48.3%)
 West 61,341 (23.2%) 66,483 (19.9%)
Income quartile <0.0001
 1 (lowest) 71,708 (27.1%) 80,999 (24.3%)
 2 73,961 (27.9%) 81,652 (24.4%)
 3 65,703 (24.9%) 84,284 (25.3%)
 4 (highest) 53,298 (20.1%) 86,579 (26.0%)
Education quartile <0.0001
 1 (lowest) 73,772 (27.9%) 78,910 (23.7%)
 2 71,656 (27.1%) 79,577 (23.8%)
 3 64,036 (24.1%) 84,386 (25.3%)
 4 (highest) 55,206 (20.9%) 90,641 (27.2%)
Primary care physician density <0.0001
 1 (lowest) 65,696 (24.8%) 72,196 (21.7%)
 2 67,782 (25.6%) 74,952 (22.5%)
 3 64,513 (24.4%) 85,335 (25.6%)
 4 (highest) 66,679 (25.2%) 101,031 (30.3%)
Urologist density <0.0001
 1 (lowest) 67,707 (25.6%) 70,576 (21.2%)
 2 72,159 (27.2%) 81,485 (24.4%)
 3 66,409 (25.1%) 86,244 (25.8%)
 4 (highest) 58,395 (22.1%) 95,209 (28.6%)
State buy-in <0.0001
 No 234,358 (88.5%) 298,652 (89.5%)
 Yes 30,312 (11.5%) 34,862 (10.5%)
PSA, prostate-specific antigen; SD, standard deviation.
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more likely to live in the South and reside in regions with 
a higher median income and educational level as well as in 
regions with a greater density of primary care providers and 
urologists.
The monthly frequencies of PSA testing according to 
receipt of previous screening are shown in Fig. 1. Within a 
given month, the screening rates were consistently higher for 
men with previous screening (typically 13%–16% of those due 
for screening) than for men without testing in the previous 2 
years (typically 3%–4%). For men without previous screen-
ing, there was a decline in the frequency of testing accord-
ing to calendar year, and this was most pronounced in 2012 
(Fig. 2). Compared with 2009, the corresponding odds ratios 
were 0.98 [95% confidence interval (CI) 0.96–1.00] in 2010, 
0.94 (95% CI 0.92–0.95) in 2011, and 0.66 (95% CI 0.65–0.68) 
in 2012. In contrast for men with previous screening, the test-
ing frequencies were relatively constant from 2009 to 2011, 
and declined more modestly in 2012. The corresponding odds 
ratios were 0.98 (95% CI 0.97–0.99) in 2010, 0.99 (95% CI 
0.98–1.00) in 2011, and 0.80 (95% CI 0.79–0.81) in 2012. In 
addition, for both groups and all study years, use of PSA test-
ing tended to be higher in the earlier part of the calendar year 
than in the later part.
The results of the multivariate GEE analyses for men 
with previous PSA testing are shown in Table 2. PSA test-
ing was less common in African Americans and men in the 
northeastern United States. There was minimal or no asso-
ciation of median income or density of primary care physi-
cians, but screening tended to be more frequent in regions 
with higher median educational levels. However, PSA testing 
use was highest in regions with a greater density of urologists. 
There was no substantive association of calendar year through 
2011 with PSA testing use, but use did decline in 2012.
In contrast, the multivariate results of PSA testing among 
men without previous screening differed across many para-
meters (Table 3). In this group, there was a pronounced decline 
with older ages, but an increase in PSA testing use with higher 
levels of comorbidity. African Americans were less likely but 
members of other racial groups were more likely to be tested. 
The highest use of testing was found in the southern United 
States, and PSA testing use tended to be highest in regions 
with higher median income and educational level. In contrast 
to men with previous screening, there was no consistent asso-
ciation with urologist density. Also, in contrast to the previ-
ously screened men, the frequency of PSA testing declined 
over time in men without recent screening, especially for 2012.
Discussion
Although prostate carcinoma is commonly diagnosed and is 
a leading cause of cancer-related death among men, the ben-
efits and harms of PSA screening for this cancer in the general 
12
13
14
15
16
17
18
0 1 2 3 4 5 6 7 8 9 10 11 12
Sc
re
en
ed
 (%
)
Month
2009 2010 2011 2012
Fig. 1. Monthly rates of prostate-specific antigen testing in men with 
previous testing. The rates remained fairly constant until 2012, when 
they declined.
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Fig. 2. Monthly rates of prostate-specific antigen testing in men 
without previous testing. The rates declined in each year of the 
analysis.
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Table 2. Multivariate analysis of prostate-specific antigen testing 
among men with previous prostate-specific antigen testing and due 
for repeated testing
 Adjusted 
OR
 
 
95% Confidence 
limits
P
Lower Upper
Age group (years)     
 67–69  Referent    
 70–74  1.04  1.02 1.05 <0.0001
 75–79  0.99  0.97 1.00 0.0376
 80+  0.76  0.75 0.77 <0.0001
Race     
 White  Referent    
 African American 0.92  0.90 0.94 <0.0001
 Other  1.05  1.03 1.08 <0.0001
Comorbidity score     
 0  Referent    
 1  1.06  1.05 1.07 0.0844
 2  1.04  1.03 1.06 0.0643
 3+  0.95  0.94 0.96 0.6796
Geographic region     
 Northeast  Referent    
 Midwest  0.78  0.77 0.80 <0.0001
 South  0.93  0.91 0.95 <0.0001
 West  0.86  0.84 0.88 <0.0001
Income quartile     
 1 (lowest)  0.98  0.96 1.00 0.0560
 2  0.98  0.96 1.00 0.0203
 3  0.98  0.97 1.00 0.0164
 4 (highest)  Referent    
Education quartile     
 1 (lowest)  0.88  0.86 0.89 <0.0001
 2  0.90  0.88 0.91 <0.0001
 3  0.96  0.95 0.98 <0.0001
 4 (highest)  Referent    
Primary care 
physician density
    
 1 (lowest)  1.00  0.96 1.04 0.9416
 2  1.00  0.97 1.03 0.9720
 3  0.98  0.96 1.00 0.0602
 4 (highest)  Referent    
Urologist density     
 1 (lowest)  0.88  0.84 0.91 <0.0001
 2  0.90  0.87 0.93 <0.0001
 3  0.92  0.90 0.95 <0.0001
 4 (highest)  Referent    
 Adjusted 
OR
 
 
95% Confidence 
limits
P
Lower Upper
Calendar year     
 2009  Referent    
 2010  0.98  0.97 0.99 <0.0001
 2011  0.99  0.98 1.00 0.0175
 2012  0.80  0.79 0.81 <0.0001
Time since last PSA 
test (years)
1.002  1.002 1.002 <0.0001
State buy-in     
 No  Referent    
 Yes  0.95  0.93 0.97 <0.0001
OR, odds ratio; PSA, prostate-specific antigen.
Table 2 (continued)
population are controversial. Consequently, given the concerns 
about false positive tests, overdiagnosis, and overtreatment, 
none of the current practice guidelines recommend universal 
screening [3–6]. Our study, which used a longitudinal design 
as opposed to the cross-sectional design from previous reports, 
found that testing patterns differed significantly depending 
on whether a patient had received PSA testing in the past. 
Whereas the rates of PSA testing declined over time among 
previously unscreened men, screening frequency remained 
more constant among men with evidence of prior PSA testing. 
In addition, although guidelines generally do not recommend 
screening in men aged 70–75 years or older [3–6], there was 
much less of a drop off in testing with age among men with 
previous PSA screening. The findings suggest that once a man 
is enrolled in a screening program, there is lower impact of 
changes in external practice guidelines.
Our study also found that for men without previous screen-
ing, an increase in PSA testing was associated with increased 
comorbidity, and a decrease was associated with advancing 
age. Although the comorbidity findings appear counterintui-
tive [25], it may reflect more frequent contact with health care 
providers and hence a greater opportunity to order PSA test-
ing. In addition, previous studies have documented aggres-
sive treatment of low-risk prostate cancer among men with 
significant comorbidity [26], suggesting that in contrast to 
Cooper et al.
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Table 3. Multivariate analysis of prostate-specific antigen testing 
among men with no prostate-specific antigen testing in the previous 
2 years
Adjusted 
OR
95% Confidence 
limits
P
Lower Upper
Age group (years)
 67–69 Referent
 70–74 0.96 0.94 0.98 <0.0001
 75–79 0.84 0.82 0.86 <0.0001
 80+ 0.57 0.56 0.59 <0.0001
Race
 White Referent
 African American 0.92 0.90 0.95 <0.0001
 Other 1.18 1.15 1.21 <0.0001
Comorbidity score
 0 Referent
 1 1.53 1.50 1.55 <0.0001
 2 1.46 1.43 1.50 <0.0001
 3+ 1.40 1.37 1.43 <0.0001
Geographic region
 Northeast Referent
 Midwest 0.88 0.85 0.90 <0.0001
 South 1.51 1.47 1.55 <0.0001
 West 1.05 1.02 1.08 0.0014
Income quartile
 1 (lowest) 0.80 0.78 0.83 <0.0001
 2 0.80 0.78 0.82 <0.0001
 3 0.85 0.83 0.87 <0.0001
 4 (highest) Referent
Education quartile
 1 (lowest) 0.88 0.86 0.91 <0.0001
 2 0.91 0.89 0.94 <0.0001
 3 0.95 0.93 0.97 <0.0001
 4 (highest) Referent
Primary care 
physician density
 1 (lowest) 0.79 0.75 0.83 <0.0001
 2 0.85 0.81 0.89 <0.0001
 3 0.97 0.94 0.99 0.0199
 4 (highest) Referent
Urologist density
 1 (lowest) 1.02 0.97 1.07 0.4534
 2 0.93 0.89 0.97 0.0003
 3 0.90 0.88 0.93 <0.0001
 4 (highest) Referent
age, clinicians may have difficulty assessing competing risks 
of comorbid illnesses. We found that in both the previously 
screened individuals and the unscreened individuals, the rate 
of PSA testing was somewhat lower in African American 
men compared with white men. Although the prostate cancer 
incidence and mortality are higher in African Americans [1], 
screening guidelines that stratify recommendations by race [5] 
differentiate only the age to start screening. Previous studies 
in younger men [20, 22, 25] and Medicare patients [11] showed 
either no racial disparity in PSA testing use [11, 20, 22] or only 
a modest difference [25].
Prior studies used administrative data from Medicare 
beneficiaries and the Department of Veterans Affairs as 
well as population-based surveys to examine the use of PSA 
testing according to patient characteristics, physician fac-
tors, geographic region, and changes in practice guidelines 
[7–12]. Using a cross-sectional approach, these studies found 
PSA rates of up to 40%–50% during a defined time period, 
with only a modest decline with advancing age and comor-
bidity. There was also significant variability in the rate of 
PSA testing among primary care providers [11], and it was 
more common in regions with greater total expenditures 
and end-of-life care [12]. Following publication of the 2008 
USPSTF guidelines recommending routine screening not 
be performed in men older than 75 years, studies reported 
a modest decline in screening rates [8, 11, 13]. In addition, 
publication of clinical trial data was also associated with a 
Adjusted 
OR
95% Confidence 
limits
P
Lower Upper
Calendar year
 2009 Referent
 2010 0.98 0.96 1.00 0.0240
 2011 0.94 0.92 0.95 <0.0001
 2012 0.66 0.65 0.68 <0.0001
State buy-in
 No Referent
 Yes 1.04 1.01 1.06 0.0034
OR, odds ratio.
Table 3 (continued)
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small decrease in the use of screening [9]. Previous studies 
from single institutions also examined the potential impact 
of the 2012 USPSTF guidelines on screening. These stud-
ies documented a decline in the overall rate of PSA testing 
among primary care providers [16] and in prostate biopsies 
[15]. Three recently published articles used the National 
Health Interview Survey to examine PSA testing receipt 
before and after the publication of the 2012 USPSTF guide-
lines. One study found that although there was a significant 
decline in testing in men older than 50 years, there contin-
ued to be a high frequency of screening in men older than 
75 years and/or with significant comorbidity [20]. Another 
study found that screening frequency increased from 2005 
to 2008 but declined from 2010 to 2013, which correlated 
with a decrease in early-stage cancer incidence [21]. A third 
study found that the decrease in PSA testing from 2010 to 
2013 was limited only to men younger than 75 years [22]. 
In contrast, an analysis of the 2012 Behavioral Risk Factor 
Surveillance System data reported only a minimal decline in 
PSA testing receipt, with an estimate of 37.1% receiving PSA 
testing among men aged 50 years or older [16]. Because of 
differences in study design (cross-sectional vs. longitudinal) 
and use of monthly as opposed to yearly rates, the proportion 
of men with screening cannot be directly compared with our 
findings. However, the temporal trends that were observed 
were evident in most studies, including our own.
We recognize several important limitations with the use 
of Medicare claims data to measure PSA testing. First, the 
data were collected for billing purposes and not research, 
and thus lacked any clinical detail. For screening procedures, 
this includes the inability to differentiate screening versus 
surveillance or diagnostic indications, although we used a 
previously validated algorithm with a higher specificity for 
screening indications [6] and excluded men with a previous 
prostate cancer diagnosis. In addition, the accuracy of claims 
data for measuring PSA testing use is thought to be high [27]. 
Our study design also could not measure patient and physi-
cian preferences regarding screening, both of which were 
likely associated with screening receipt. However, the results 
were clustered by provider, which accounts in part for phy-
sician practice patterns. Because of incomplete claims data, 
the study did not include men who were enrolled in Medicare 
Advantage Plans or those not enrolled in Medicare Part B, 
and it was not known if the trends of PSA testing use in these 
groups would be similar. The study was also limited to an 
older patient population, and thus the impact of guidelines and 
other factors in younger, privately insured individuals could 
not be measured. Moreover, despite the lack of USPSTF rec-
ommendations, PSA testing has remained a covered benefit 
under Medicare without any out-of-pocket expenses. Analyses 
in younger patient groups have found mixed results with 
regard to changes in PSA testing uptake after 2012 [20–22]. 
Finally, because patient-level socioeconomic status was not 
available in claims data, we used small area measures, a com-
monly used approach in studies of Medicare data.
In summary, we found that receipt of PSA testing is highly 
dependent on whether an individual was tested in the recent 
past. Although overall rates of PSA testing use declined with 
time, the largest decrease occurred in both previously screened 
and unscreened men in 2012, which may reflect publication of 
the most recent USPSTF guidelines.
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Significance statement
Universal screening for prostate cancer with prostate specific 
antigen (PSA) testing in men has not been recommended by 
the US Preventive Services Task Force since 2012 and had an 
indeterminate recommendation prior to that. However, previ-
ous studies that have shown changes following guidelines have 
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not considered whether men were already undergoing screen-
ing. Using a population-based sample of Medicare beneficiar-
ies, we found that among previously unscreened men, there was 
a significant decline in testing from 2009–2012 that was most 
pronounced in 2012. In contrast for men already screened, the 
decline was much less apparent. The findings suggest that receipt 
of PSA, including after the 2012 guidelines, is highly dependent 
on whether an individual was tested in the recent past.
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